{"abstract": "The $181 million agreement ends state consumer fraud complaints about the subsidiary\u2019s off-label marketing of the antipsychotic drug.", "web_url": "https://www.nytimes.com/2012/08/31/business/johnson-johnson-unit-settles-state-cases-over-risperdal.html", "snippet": "The $181 million agreement ends state consumer fraud complaints about the subsidiary\u2019s off-label marketing of the antipsychotic drug.", "lead_paragraph": "Johnson & Johnson announced Thursday that its pharmaceutical unit had reached a $181 million consumer fraud settlement with 36 states and the District of Columbia over its marketing of Risperdal, an antipsychotic drug.", "print_section": "B", "print_page": "3", "source": "The New York Times", "multimedia": [], "headline": {"main": "Johnson & Johnson Unit Settles State Cases Over Risperdal", "kicker": null, "content_kicker": null, "print_headline": "J.&J. Unit Settles Cases With States On Risperdal", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Mental Health and Disorders", "rank": 1, "major": "N"}, {"name": "subject", "value": "Frauds and Swindling", "rank": 2, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Janssen Pharmaceutica", "rank": 4, "major": "N"}, {"name": "organizations", "value": "Johnson & Johnson", "rank": 5, "major": "N"}, {"name": "subject", "value": "Suits and Litigation", "rank": 6, "major": "N"}], "pub_date": "2012-08-30T19:48:42+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Katie Thomas", "person": [{"firstname": "Katie", "middlename": null, "lastname": "Thomas", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/c2a33bd5-919e-5108-ae06-a64b50f7426e", "word_count": 505, "uri": "nyt://article/c2a33bd5-919e-5108-ae06-a64b50f7426e"}